Featured Research

from universities, journals, and other organizations

New clues to Epstein-Barr virus

Date:
February 21, 2013
Source:
Beth Israel Deaconess Medical Center
Summary:
Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

The new findings, which currently appear on-line in Cell Reports, reinforce current directions being taken in the development of a vaccine to guard against EBV, and raise important new questions regarding the virus's possible relationship to malaria and to autoimmune diseases.

"Our discovery that CD35 is an attachment receptor for EBV helps explain several previously unsolved observations," explains the study's senior author Joyce Fingeroth, MD, a member of the Division of Infectious Disease at BIDMC and Associate Professor of Medicine at Harvard Medical School.

First discovered in the early 1960s, EBV is one of eight viruses in the human herpesvirus family. The virus affects nine out of 10 people at some point in their lifetimes.

Infections in early childhood often cause no disease symptoms, but people infected during adolescence or young adulthood may develop infectious mononucleosis. EBV is also associated with several types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma and nasopharyngeal carcinoma, and has been linked to certain autoimmune disorders.

"EBV was the first human virus that was discovered to be a tumor virus," explains Fingeroth. "In fact, individuals who have had infectious mononucleosis have a four times increased risk of developing Hodgkin's disease." After the initial infection, the EBV virus remains in a person's body for life.

To gain entry, viruses must first attach to their host cells. For herpesviruses, receptors on the viral envelope become connected to complementary receptors on the cell membrane. In the case of EBV, the virus gains access to the immune system by attaching to primary B cells.

Nearly 30 years ago, Fingeroth and her colleagues discovered that this attachment occurs via the CD21 protein, which until now was the only known B cell attachment receptor for EBV. The recent finding that B cells from a patient lacking CD21 can be infected and immortalized by EBV had indicated that an alternative attachment receptor must exist. The identification of this second receptor -- CD35 -- by Fingeroth's team, led by first author Javier Ogembo, PhD, of BIDMC and the University of Massachusetts Medical School, not only underscores an important finding regarding primary infection but also underscores the importance of EBVgp350/220, (the virus protein that has been found to bind to both attachment receptors) for the development of a vaccine against EBV.

"The EBV glycoprotein gp350/220, is the most abundant surface glycoprotein on the virus," says Fingeroth, adding that these results further suggest the virus fusion apparatus is the same for both receptors. "An EBV vaccine might be able to prevent infection or, alternatively, greatly reduce a person's risk of developing infectious mononucleosis and EBV-associated cancers, without necessarily preventing the EBV infection itself," she explains.

Interestingly, whereas a human has now been identified to be lacking the CD21 receptor, no persons are known to lack CD35. "CD35 is a latecomer in evolution and in its current form, exists only in humans," says Fingeroth. "We know that it is often targeted in autoimmune diseases and was recently identified as a malaria receptor. Our new discovery may, therefore, reveal new avenues for the exploration of unexplained links between EBV, autoimmune disease, malaria, and cancer."

In addition to Fingeroth and Ogembo, study coauthors include BIDMC investigators Lakshmi Kannan, Ionita Ghiran, Anne Nicholson-Weller and George Tsokos; and UMass investigator Robert Finberg.

This study was supported by a grant from the National Institutes of Health (R01A10635710) as well as support from the American Heart Association, the St. Baldrick's Foundation, and the Cancer Research Institute.


Story Source:

The above story is based on materials provided by Beth Israel Deaconess Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. JavierG. Ogembo, Lakshmi Kannan, Ionita Ghiran, Anne Nicholson-Weller, Robert W. Finberg, GeorgeC. Tsokos, JoyceD. Fingeroth. Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor. Cell Reports, 2013; 3 (2): 371 DOI: 10.1016/j.celrep.2013.01.023

Cite This Page:

Beth Israel Deaconess Medical Center. "New clues to Epstein-Barr virus." ScienceDaily. ScienceDaily, 21 February 2013. <www.sciencedaily.com/releases/2013/02/130221152738.htm>.
Beth Israel Deaconess Medical Center. (2013, February 21). New clues to Epstein-Barr virus. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2013/02/130221152738.htm
Beth Israel Deaconess Medical Center. "New clues to Epstein-Barr virus." ScienceDaily. www.sciencedaily.com/releases/2013/02/130221152738.htm (accessed July 25, 2014).

Share This




More Plants & Animals News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How to Make Single Serving Smoothies: Howdini Hacks

How to Make Single Serving Smoothies: Howdini Hacks

Howdini (July 24, 2014) Smoothies are a great way to get in lots of healthy ingredients, plus they taste great! Howdini has a trick for making the perfect single-size smoothie that will save you time on cleanup too! All you need is a blender and a mason jar. Video provided by Howdini
Powered by NewsLook.com
Boy Attacked by Shark in Florida

Boy Attacked by Shark in Florida

Reuters - US Online Video (July 24, 2014) An 8-year-old boy is bitten in the leg by a shark while vacationing at a Florida beach. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Goma Cheese Brings Whiff of New Hope to DRC

Goma Cheese Brings Whiff of New Hope to DRC

Reuters - Business Video Online (July 24, 2014) The eastern region of the Democratic Republic of Congo, mainly known for conflict and instability, is an unlikely place for the production of fine cheese. But a farm in the village of Masisi, in North Kivu is slowly transforming perceptions of the area. Known simply as Goma cheese, the Congolese version of Dutch gouda has gained popularity through out the region. Ciara Sutton reports. Video provided by Reuters
Powered by NewsLook.com
Tyrannosaur Pack-Hunting Theory Aided By New Footprints

Tyrannosaur Pack-Hunting Theory Aided By New Footprints

Newsy (July 24, 2014) A new study claims a set of prehistoric T-Rex footprints supports the theory that the giant predators hunted in packs instead of alone. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins